source
- Lilly advances retatrutide toward sleep-apnea marketEli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…
- Biotech reverse mergers rebound to highest level since 2021 as PIPEs flood market: reportReverse mergers have returned with a bang. More biotechs have taken the back door to the public markets so far in 2026 than in any full year since 2021, according to J.P. Morgan, with institutional…Fierce Biotech · 5h ago↗ source
- Rapport Therapeutics' epilepsy drug RAP-219 meets primary endpoint in bipolar mania Phase II trial